Gregory Yh Lip

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. ncbi Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study
    Gregory Y H Lip
    From the University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom G Y H L and Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada J E, S Y, O S, R G H, S C
    Stroke 45:2127-30. 2014
  2. ncbi Circulating microparticles: challenges and perspectives of flow cytometric assessment
    Eduard Shantsila
    Prof Gregory Y H Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK, Tel 44 121 507 5080, Fax 44 121 507 5907, E mail
    Thromb Haemost 111:1009-14. 2014
  3. ncbi Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
    James Foley
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, United Kingdom
    Curr Vasc Pharmacol 12:373-83. 2014
  4. ncbi Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database
    Gregory Y H Lip
    Professor G Y H Lip, University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK, Tel 44 121 5075080, Fax 44 121 554 4083, E mail
    Thromb Haemost 111:933-42. 2014
  5. pmc Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis
    Lars Hvilsted Rasmussen
    Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
    BMJ 345:e7097. 2012
  6. pmc Stroke Prevention in Atrial Fibrillation: Where are We Now?
    Yousif Ahmad
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Clin Med Insights Cardiol 6:65-78. 2012
  7. pmc Management of atrial fibrillation
    Puneet Kakar
    Hemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Vasc Health Risk Manag 3:109-16. 2007
  8. ncbi Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom Electronic address
    Clin Ther 36:192-210.e20. 2014
  9. doi Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study)
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom Electronic address
    Am J Cardiol 113:480-4. 2014
  10. ncbi Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial
    S Apostolakis
    Prof G Y H Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK, Tel 44 0 121 507 5080, Fax 44 0 121 554 4083, E mail
    Thromb Haemost 110:1074-9. 2013

Detail Information

Publications207 found, 100 shown here

  1. ncbi Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study
    Gregory Y H Lip
    From the University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom G Y H L and Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada J E, S Y, O S, R G H, S C
    Stroke 45:2127-30. 2014
    ..Female patients with atrial fibrillation are at increased stroke risk compared with male patients, and the underlying reasons for higher risk are uncertain...
  2. ncbi Circulating microparticles: challenges and perspectives of flow cytometric assessment
    Eduard Shantsila
    Prof Gregory Y H Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK, Tel 44 121 507 5080, Fax 44 121 507 5907, E mail
    Thromb Haemost 111:1009-14. 2014
    ..This viewpoint manuscript provides a critical summary of the key methodological aspects of microparticle analysis. ..
  3. ncbi Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
    James Foley
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, United Kingdom
    Curr Vasc Pharmacol 12:373-83. 2014
    ..Three novel oral anticoagulants have just completed Phase III trials for stroke prevention, all with impressive results; the direct thrombin inhibitor, dabigatran and the oral factor Xa inhibitors, rivaroxaban and apixaban. ..
  4. ncbi Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database
    Gregory Y H Lip
    Professor G Y H Lip, University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK, Tel 44 121 5075080, Fax 44 121 554 4083, E mail
    Thromb Haemost 111:933-42. 2014
    ..Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both efficacy and safety. ..
  5. pmc Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis
    Lars Hvilsted Rasmussen
    Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
    BMJ 345:e7097. 2012
    ..A secondary objective was to do the same analysis in the primary prevention cohort...
  6. pmc Stroke Prevention in Atrial Fibrillation: Where are We Now?
    Yousif Ahmad
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Clin Med Insights Cardiol 6:65-78. 2012
    ..The landscape of stroke prevention in AF has changed with effective alternatives to warfarin available for the first time in 60 years-but each new option brings new considerations...
  7. pmc Management of atrial fibrillation
    Puneet Kakar
    Hemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Vasc Health Risk Manag 3:109-16. 2007
    ....
  8. ncbi Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom Electronic address
    Clin Ther 36:192-210.e20. 2014
    ..Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF)...
  9. doi Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study)
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom Electronic address
    Am J Cardiol 113:480-4. 2014
    ..To enhance pericardioversion stroke prevention, cardioversion algorithms should focus less on the type of conversion and more on stroke risk factors and atrial fibrillation duration...
  10. ncbi Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial
    S Apostolakis
    Prof G Y H Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK, Tel 44 0 121 507 5080, Fax 44 0 121 554 4083, E mail
    Thromb Haemost 110:1074-9. 2013
    ..Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS2 or CHA2DS2-VASc scores should not be used. ..
  11. doi Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom
    Circ Arrhythm Electrophysiol 5:941-8. 2012
    ....
  12. doi Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation
    Pilar Gallego
    Prof G Y H Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK, Tel 44 121 5075080, Fax 44 121 554 4083, E mail
    Thromb Haemost 110:1189-98. 2013
    ..Specifically, VKA cessation independently increased the risk of stroke, even after adjusting for CHA₂DS₂-VASc score. TTR was an independent risk factor for major bleeding following initiation of VKA therapy...
  13. ncbi Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, United Kingdom Electronic address
    Int J Cardiol 168:1832-6. 2013
    ..It remains uncertain whether the HAS-BLED score could identify non-AF individuals at risk of developing intracranial haemorrhage (ICH), which is the most intractable and devastating major bleeding complication...
  14. ncbi Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, United Kingdom
    Int J Cardiol 168:414-9. 2013
    ..We hypothesized that contemporary stroke risk stratification schemes used in assessing AF patients could predict stroke and thromboembolism in a non-AF community population, comparably to that seen in AF populations...
  15. pmc RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers
    Harry J G M Crijns
    Maastricht University Medical Center, Maastricht, Netherlands
    BMC Cardiovasc Disord 12:85. 2012
    ..There are limited data on the variation in treatment practice patterns across different countries, healthcare settings and the associated health outcomes...
  16. doi Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction
    Eduard Shantsila
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 110:340-8. 2013
    ..This may represent a regulatory feed-back mechanism aiming to re-balance the marked inflammation which is typically present following acute MI or selective homing of monocytes with high receptor expression to damaged myocardium. ..
  17. ncbi Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK
    Circ J 77:1380-8. 2013
    ..Irrespective of age, treatment decisions regarding stroke thromboprophylaxis in all patients with AF should be based on consideration of individual potential benefits and risks of treatment and patient preferences.  ..
  18. doi Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary
    G Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Thromb Haemost 11:615-26. 2013
    ....
  19. ncbi Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
    Nicoletta Riva
    University of Birmingham Centre for Cardiovascular Sciences, Birmingham, United Kingdom
    Curr Pharm Des 19:3753-65. 2013
    ..This review will focus on the rationale and current evidences about combination therapy in the management of arterial hypertension...
  20. doi Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    V Roldan
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 109:956-60. 2013
    ..Adding CKD to the CHADS2 and CHA2DS2-VASc stroke risk scores did not independently add predictive information...
  21. doi Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis
    Ida Ehlers Albertsen
    Department of Cardiology, Aalborg AF Study Group, Aalborg University Hospital, Aalborg, Denmark
    Stroke 44:1329-36. 2013
    ..Our aim was to identify the risk factors that contribute to stroke risk in atrial fibrillation, although patients were taking OACs in a clinical trial setting...
  22. ncbi Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Circ Arrhythm Electrophysiol 6:31-8. 2013
    ..The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated...
  23. doi Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?
    William M O'Neil
    LA SER Group, Montreal, Canada
    Thromb Haemost 109:497-503. 2013
    ..Although there are differences in outcome between PROBE and double blind trials, they do not appear to be design-related. The exacting requirements of double-blinding in AF trials may not be necessary...
  24. doi Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey
    Ron Pisters
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 109:328-36. 2013
    ..In conclusion, based on this modelling exercise, the utilisation of apixaban and dabigatran for thromboprophylaxis could provide a profound annual mathematical net clinical benefit on stroke and major bleeds, in European AF patients...
  25. doi Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of the European Heart Rhythm Association survey
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, England, UK
    Europace 15:141-3. 2013
    ..Experience varied widely, and this was reflected in the wide range of thromboembolic and procedural (tamponade, bleeding) complications reported by the respondents to this EP wire survey...
  26. doi The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England
    Chest 142:1489-98. 2012
    ..The objective of this study was to undertake a systematic review of the published literature on the epidemiology of AF in other regions...
  27. pmc Stroke prevention in atrial fibrillation: concepts and controversies
    Yousif Ahmad
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Curr Cardiol Rev 8:290-301. 2012
    ..Monitoring, reversal, and perioperative management are areas which require further investigation to enhance our ability to safely and effectively utilise the new agents...
  28. doi Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 108:1009-22. 2012
    ..Novel oral anticoagulants that offer a different risk-benefit profile compared with warfarin may appear as an attractive therapeutic option, but this would need to be confirmed in clinical trials...
  29. doi Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK
    Eur J Heart Fail 14:681-95. 2012
    ..New oral anticoagulants that offer a different risk-benefit profile compared with warfarin may appear as an attractive therapeutic option, but this would need to be confirmed in clinical trials...
  30. ncbi Insights from the RCPE UK Consensus Conference on approaching the comprehensive management of atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, B18 7QH, UK
    Expert Rev Cardiovasc Ther 10:697-700. 2012
    ..The Consensus Statement and its background papers are recommended reading for the development of local guidelines for management, and for the management of individual patients...
  31. doi An innovative flow cytometric approach for small-size platelet microparticles: influence of calcium
    Silvia Montoro-García
    Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 108:373-83. 2012
    ..In conclusion, we present a sensitive protocol for the analysis of circulating and in vitro induced small-size PMPs that might contribute to future cardiovascular and clinical research...
  32. doi Anticoagulation versus placebo for heart failure in sinus rhythm
    Gregory Yh Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Cochrane Database Syst Rev 6:CD003336. 2012
    ....
  33. doi Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways
    Eduard Shantsila
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 108:32-40. 2012
    ..These changes could reflect the role of these factors in post-MI myocardial healing. Monocyte-platelet interactions are independently associated with the regulation of the fibrinolytic status in ACS...
  34. doi Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, England, UK
    Europace 14:741-4. 2012
    ..The results of this survey show variation in clinical practice, but reassuringly some consistency with guidelines and consensus recommendations on the management of periprocedure (devices, ablation) antithrombotic therapy...
  35. ncbi What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
    G Y H Lip
    University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH England, UK
    J R Coll Physicians Edinb 42:35-44. 2012
    ....
  36. ncbi Atrial fibrillation in 2011: Stroke prevention in AF
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK
    Nat Rev Cardiol 9:71-3. 2012
    ..Patients with ≥ 1 stroke risk factors can be considered for oral anticoagulation. These novel, fixed-dose drugs are given without monitoring, so clinicians must learn to balance stroke and bleeding risks...
  37. doi Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study
    Amitava Banerjee
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Haemost 107:584-9. 2012
    ..Using 'real world' data, our modelling analysis has shown that when the risk of bleeding and stroke are both high, all three new drugs appear to have a greater net clinical benefit compared to warfarin...
  38. doi Atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Lancet 379:648-61. 2012
    ..The availability of non-pharmacological approaches, such as ablation, has allowed additional options for the management of atrial fibrillation in patients who are unsuitable for or intolerant of drug approaches...
  39. ncbi Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents
    Burak Pamukcu
    Centre for Cardiovascular Sciences, City Hospital, B18 7QH, Birmingham, England, UK
    Curr Pharm Des 18:850-60. 2012
    ..Further agents with antiplatelet properties are being investigated at present. This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases...
  40. pmc Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John J You
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 141:e531S-75S. 2012
    ..We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios...
  41. pmc 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?
    Eduard Shantsila
    J Transl Med 6:47. 2008
    ....
  42. pmc Clinical review: clinical management of atrial fibrillation - rate control versus rhythm control
    Hoong Sern Lim
    University Department of Medicine, City Hospital, Birmingham, UK
    Crit Care 8:271-9. 2004
    ..Regardless of approach, continuous therapeutic anticoagulation is crucial for stroke prevention. This review addresses the findings of these studies and their implications for clinical management of patients with atrial fibrillation...
  43. pmc Cross-cultural adaptation into Punjabi of the English version of the Hospital Anxiety and Depression Scale
    Deirdre A Lane
    University Department of Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK
    BMC Psychiatry 7:5. 2007
    ..The aim of the study was to translate and validate the Hospital Anxiety and Depression Scale into Punjabi...
  44. pmc Validation of the Edinburgh Claudication Questionnaire in 1st generation Black African-Caribbean and South Asian UK migrants: a sub-study to the Ethnic-Echocardiographic Heart of England Screening (E-ECHOES) study
    Philip C Bennett
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Department of Vascular Surgery, Edgbaston, Birmingham B15 2TT, UK
    BMC Med Res Methodol 11:85. 2011
    ..We also determined the diagnostic accuracy of translated versions of the ECQ in 1st generation South Asian UK migrants, as this has not been investigated before...
  45. pmc Recruitment of ethnic minority patients to a cardiac rehabilitation trial: the Birmingham Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263]
    Kate Jolly
    Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham B15 2TT, England
    BMC Med Res Methodol 5:18. 2005
    ....
  46. pmc Blood pressure demographics: nature or nurture ... ... genes or environment?
    Joseph Tomson
    University Department of Medicine, City Hospital, Birmingham B18 7QH, England, UK
    BMC Med 3:3. 2005
    ..Examining the non-genetic influences in future hypertension research may be necessary in order to clearly define the local blood pressure demographics and the global hypertensive disease burden...
  47. pmc Self-care and adherence to medication: a survey in the hypertension outpatient clinic
    Faekah Gohar
    Dept Public Health, University of Birmingham, Birmingham, B15 2TT, UK
    BMC Complement Altern Med 8:4. 2008
    ..Adherence to medication is important for blood pressure control, but poor adherence is common. The study aimed to determine the prevalence of self-care behaviours in patients attending a secondary care hypertension clinic...
  48. pmc Diabetes Health, Residence & Metabolism in Asians: the DHRMA study, research into foods from the Indian subcontinent - a blinded, randomised, placebo controlled trial
    Jeetesh V Patel
    Metabolic Medicine, Sandwell General Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Lyndon, West Bromwich, Lyndon B71 4HJ, UK
    BMC Cardiovasc Disord 11:70. 2011
    ..Dietary intervention is an important and first line approach to manage increased CHD risk. However, there is limited information on the impact of the South Asian diet on CHD risk...
  49. pmc A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732]
    Dawn Swancutt
    Department of Primary Care and General Practice, The University of Birmingham, UK
    BMC Cardiovasc Disord 4:12. 2004
    ..The value of clinical assessment and echocardiography as additional methods of risk stratification for thromboembolic disease in patients with AF were also evaluated...
  50. pmc Rationale and study design of a cross sectional study documenting the prevalence of Heart Failure amongst the minority ethnic communities in the UK: the E-ECHOES Study (Ethnic--Echocardiographic Heart of England Screening Study)
    Paramjit S Gill
    Primary Care Clinical Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    BMC Cardiovasc Disord 9:47. 2009
    ....
  51. pmc TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)
    Danielle E Smith
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, B18 7QH, UK
    BMC Cardiovasc Disord 10:21. 2010
    ..0 to 3.0). AF patients possess limited knowledge of their disease and warfarin treatment and this can impact on INR control. Education can improve patients' understanding of warfarin therapy and factors which affect INR control...
  52. pmc Home-based exercise rehabilitation in addition to specialist heart failure nurse care: design, rationale and recruitment to the Birmingham Rehabilitation Uptake Maximisation study for patients with congestive heart failure (BRUM-CHF): a randomised control
    Kate Jolly
    Department of Public Health and Epidemiology, Public Health Building, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
    BMC Cardiovasc Disord 7:9. 2007
    ....
  53. doi Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis
    Gregory Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, England, UK
    Thromb Haemost 100:11-3. 2008
  54. ncbi Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline
    Gregory Y H Lip
    Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK
    Chest 130:1823-7. 2006
    ....
  55. doi Antithrombotic treatment in atrial fibrillation
    G Y H Lip
    Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK
    Postgrad Med J 84:252-8. 2008
    ..Stroke is the most serious complication. Evidence from AF antithrombotic treatment trials is reviewed, risk stratification of patients with AF is discussed, and recommendations for anticoagulation are presented...
  56. ncbi Effect of hypertension on anticoagulated patients with atrial fibrillation
    Gregory Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Eur Heart J 28:752-9. 2007
    ....
  57. ncbi New approaches to therapy with omega-3 fatty acids
    Puneet Kakar
    University Department of Medicine, City Hospital, Birmingham B18 7QH, UK
    Curr Atheroscler Rep 10:79-87. 2008
    ....
  58. ncbi Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management
    G Y H Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    J Hum Hypertens 21:183-211. 2007
    ....
  59. pmc Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation
    Gregory Y H Lip
    University Department of Medicine, City Hospital, Birmingham B18 7QH
    BMJ 336:614-5. 2008
  60. ncbi High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis
    Gregory Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England, UK
    Stroke 38:1229-37. 2007
    ....
  61. ncbi Peripheral artery disease and hypertension: the relation between ankle-brachial index and mortality
    V J Karthikeyan
    University Department of Medicine, City Hospital, Birmingham, UK
    J Hum Hypertens 21:762-5. 2007
  62. ncbi Atrial fibrillation and stroke prevention
    Gregory Y H Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    Lancet Neurol 6:981-93. 2007
    ..Possible barriers to the uptake of anticoagulation therapy are also discussed...
  63. ncbi Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation
    Gregory Y H Lip
    Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England
    Stroke 37:2294-300. 2006
    ..This study determined the additive role of plasma vWf levels to clinical factors for risk stratification in patients with AF...
  64. ncbi Management of atrial fibrillation
    Gregory Y H Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    Lancet 370:604-18. 2007
    ..Electrophysiological approaches could hold some promise for a curative approach in atrial fibrillation...
  65. ncbi Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure
    Bernard S P Chin
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom
    Am J Cardiol 90:1258-60. 2002
  66. doi Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention
    Gregory Y H Lip
    University Department of Medicine, City Hospital, Birmingham B18 7QH
    BMJ 337:a840. 2008
  67. doi Can we predict stroke in atrial fibrillation?
    Gregory Y H Lip
    Centre for Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham, United Kingdom
    Clin Cardiol 35:21-7. 2012
    ..It also makes the clinician think of correctable common bleeding risk factors, and the availability of such a score allows an informed assessment of bleeding risk in AF patients, when antithrombotic therapy is being initiated...
  68. doi Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis
    Gregory Y H Lip
    Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, Birmingham B18 7QH, UK
    Thromb Haemost 106:997-1011. 2011
    ..Finally, this document puts forwards consensus statements that may help to define evidence gaps and assist in everyday clinical practice...
  69. doi Stroke in atrial fibrillation: epidemiology and thromboprophylaxis
    G Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Thromb Haemost 9:344-51. 2011
    ..The aim of the review article is to provide a state-of-the-art overview of the clinical epidemiology of stroke in AF, stroke (and bleeding) risk assessments and the current provision of thromboprophylaxis for patients with AF...
  70. ncbi Myocardial perfusion by myocardial contrast echocardiography and endothelial dysfunction in obstructive sleep apnea
    Mehmood Butt
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, England, UK
    Hypertension 58:417-24. 2011
    ....
  71. doi Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK
    Europace 13:723-46. 2011
    ..Nonetheless, identification of patients at high risk of bleeding and delineation of conditions and situations associated with bleeding risk can help to refine antithrombotic therapy to minimize bleeding risk...
  72. doi Peri-operative management of ophthalmic patients taking antithrombotic therapy
    G Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Int J Clin Pract 65:361-71. 2011
    ..The risk of thrombosis-related complications on disruption of anticoagulation may be higher than the risk of significant bleeding by continuing its use for most types of ophthalmic surgery...
  73. doi Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagoni
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Thromb Res 127:91-9. 2011
    ....
  74. doi Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drug
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England
    J Am Coll Cardiol 57:173-80. 2011
    ..The purpose of this study was to investigate predictors of bleeding in a cohort of anticoagulated patients and to evaluate the predictive value of several bleeding risk stratification schemas...
  75. doi A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice
    T P Van Staa
    General Practice Research Database, Medicines and Healthcare products Regulatory Agency, London, UK
    J Thromb Haemost 9:39-48. 2011
    ..The objective of this study was to compare the predictive ability of 15 published stratification schemes for stroke risk in actual clinical practice in the UK...
  76. doi Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England, UK
    Stroke 41:2731-8. 2010
    ..Among anticoagulated cohorts, the emphasis should be on the identification of patients who remain at high risk for stroke despite anticoagulation...
  77. doi Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, England, UK
    Am J Med 124:111-4. 2011
    ....
  78. doi Improving stroke risk stratification in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England
    Am J Med 123:484-8. 2010
    ..This would simplify our approach to thromboprophylaxis in patients with atrial fibrillation...
  79. ncbi Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by t
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK
    Eur Heart J 31:1311-8. 2010
    ..This executive summary highlights the main recommendations from the consensus document...
  80. pmc Endothelial progenitor cells: what use for the cardiologist?
    Aurangzeb Siddique
    Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Angiogenes Res 2:6. 2010
    ..This review article aims to provide an overview of the vast literature on EPCs in relation to clinical cardiology...
  81. pmc Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK
    Eur Heart J 30:2897-907. 2009
    ..We report from a Phase II randomized, dose-guiding study (NCT00684307) to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of extended-release AZD0837 in patients with AF...
  82. ncbi Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long enough?
    G Y H Lip
    University Department of Medicine, City Hospital, Birmingham, B18 7QH, England
    Hamostaseologie 29:96-101. 2009
    ..Apart from atrial fibrillation, there is relatively limited evidence for the role of antithrombotic therapy for other cardiac conditions associated with cardioembolism and how long one should treat...
  83. doi Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice
    Burak Pamukcu
    University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK
    Expert Opin Pharmacother 12:131-40. 2011
    ..Despite several developments in antithrombotic, antiatherosclerotic and device-based cardiac therapies, few noteworthy antiarrhythmic drugs have been developed...
  84. ncbi Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension
    G Y Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    J Hypertens 17:1203-7. 1999
    ..We hypothesized that patients with ISH would exhibit a prothrombotic state similar to that seen in SDH. A secondary hypothesis was that individuals with ISH had similar echocardiographic parameters to those seen in SDH...
  85. ncbi Changes in renal function with percutaneous transluminal coronary angioplasty
    G Y Lip
    Department of Cardiology, City Hospital, Birmingham, UK
    Int J Cardiol 70:127-31. 1999
    ....
  86. ncbi Factor X inhibitors
    Kiat Tsong Tan
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
    Expert Opin Investig Drugs 12:799-804. 2003
    ..Oral factor X inhibitors are also being developed, which may be of use in the outpatient prevention and/or treatment of stroke and thromboembolism...
  87. ncbi More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2)
    G Y H Lip
    University Department of Medicine, City Hospital, Birmingham, England, UK
    J Hum Hypertens 17:747-50. 2003
  88. ncbi Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'
    Gregory Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England
    Ann Med 36:119-25. 2004
    ..Indeed, we suggest that angiogenesis is an important aspect of the pathophysiology of cardiovascular disease, impacting with both thrombogenesis and atherogenesis, in a new vascular triad (the 'Birmingham vascular triad')...
  89. pmc Ethnic differences in patient perceptions of heart failure and treatment: the West Birmingham heart failure project
    G Y H Lip
    University Department of Medicine, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, Birmingham B18 7QH, UK
    Heart 90:1016-9. 2004
    ....
  90. ncbi Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation
    Dwayne S G Conway
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom
    Am Heart J 148:462-6. 2004
    ..We hypothesized that increased plasma levels of IL-6 and CRP, as indexes of an inflammatory state, would be associated with an increased risk of stroke and death among patients with AF...
  91. pmc Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade
    P L Lip
    University Department of Medicine, City Hospital, Birmingham B18 7QH, UK
    Br J Ophthalmol 88:1543-6. 2004
    ....
  92. ncbi Preventing stroke in atrial fibrillation: the SPORTIF programme
    Gregory Y H Lip
    University Department of Medicine, City Hospital, Birmingham B18 7QH, UK
    Pathophysiol Haemost Thromb 34:25-30. 2005
    ..With its positive benefit-risk ratio, ximelagatran may increase the population of eligible patients for anticoagulation with AF and maximize the potential of anticoagulation in the prevention of stroke...
  93. pmc Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation
    G Y H Lip
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Heart 91:759-63. 2005
    ....
  94. pmc Peripheral arterial disease: a high risk - but neglected - disease population
    Joseph Tomson
    University Department of Medicine, City Hospital, Birmingham B18 7QH, England, UK
    BMC Cardiovasc Disord 5:15. 2005
    ..With a holistic approach to atherothrombotic vascular disease, our management of PAD can only get better...
  95. pmc Antithrombotic treatment in atrial fibrillation
    G Y H Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    Heart 92:155-61. 2006
    ..In this article, the evidence for AF treatment trial of antithrombotic therapy is reviewed. Stroke risk stratification of patients with AF is discussed, and practical recommendations for thromboprophylaxis are presented...
  96. ncbi Alcohol and cardiovascular disease--more than one paradox to consider. Alcohol and hypertension--does it matter? (no!)
    Gregory Y H Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    J Cardiovasc Risk 10:11-4. 2003
    ..Indeed, hypertension is likely to be multifactorial and many factors would confound the relationship, if any, between alcohol and hypertension...
  97. ncbi Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review
    G Y H Lip
    Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
    QJM 95:451-9. 2002
    ..Long-term oral anticoagulation is established in certain groups, including patients with heart failure and atrial fibrillation, but there is wide variation in the use of oral anticoagulation in the broader heart failure population...
  98. ncbi Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project
    G Y H Lip
    Haemostasis Thrombosis Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Blood Coagul Fibrinolysis 13:339-47. 2002
    ....
  99. ncbi Serum urate is associated with baseline renal dysfunction but not survival or deterioration in renal function in malignant phase hypertension
    G Y Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    J Hypertens 18:97-101. 2000
    ..There has been speculation whether serum uric acid levels are an independent prognostic factor in patients with hypertension...
  100. ncbi Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs?
    G Y Lip
    University Department of Medicine, City Hospital, Birmingham, England
    Am J Hypertens 13:934-9. 2000
    ..6549). We suggest that MHT can occur de novo in patients without previously known hypertension, and the clinical characteristics and prognosis in such patients were similar to MHT patients with previously known hypertension...
  101. ncbi A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction
    G Y Lip
    University Department of Medicine, City Hospital, Birmingham, UK
    J Intern Med 248:316-8. 2000
    ....